Get the Stockscreener App
0.3477
6.04%
0.0198
IGC Pharma Inc stock is traded at $0.3477, with a volume of 1.40M.
It is up +6.04% in the last 24 hours and down -5.00% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.3279
Open:
$0.35
24h Volume:
1.40M
Relative Volume:
2.00
Market Cap:
$32.29M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.3373
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
+16.72%
1M Performance:
-5.00%
6M Performance:
+12.16%
1Y Performance:
-11.10%
1-Day Range:
$0.3358
$0.3579
1-Week Range:
$0.2839
$0.358
52-Week Range:
$0.2525
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.3477 | 30.45M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
IGC Pharma Inc Stock (IGC) Latest News
It is Poised to be a Bull Market for IGC Pharma Inc (IGC) - setenews.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." - Digital Journal
IGC Pharma : Announces Coverage Report by Ascendiant Capital Markets about the “Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75.” - marketscreener.com
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We - pharmiweb.com
IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation - Nasdaq
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
Ascendiant Capital Maintains IGC Pharma (IGC) Buy Recommendation - Nasdaq
IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 C - GuruFocus
IGC Achieves Significant Enrollment Progress in Phase 2 Alzheimer's Trial - GuruFocus
IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial - pharmiweb.com
Can IGC Pharma Inc. stock test all time highsEarnings Recap Report & Fast Gaining Stock Reports - Newser
Why IGC Pharma Inc. (IGS1) stock is favored by hedge fundsQuarterly Performance Summary & Fast Moving Trade Plans - Newser
Why institutional investors increase stakes in IGC Pharma Inc. (IGS1) stockInflation Watch & Fast Entry Momentum Alerts - Newser
Why IGC Pharma Inc. (IGS1) stock attracts HNW investorsBuy Signal & Weekly Breakout Watchlists - Newser
Is IGC Pharma Inc. (IGS1) stock worth holding before Fed meeting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
IGC Pharma (NYSE American: IGC) registers 978,235 shares for stockholder resale - Stock Titan
Is IGC Pharma Inc. (IGS1) stock a top pick for value investorsJuly 2025 Review & Weekly Watchlist for Consistent Profits - Newser
Is IGC Pharma Inc. stock worth holding before Fed meetingWeekly Trend Recap & Capital Efficiency Focused Ideas - Newser
Will IGC Pharma Inc. stock beat value stocksGDP Growth & Safe Capital Growth Plans - Newser
IGC Pharma Publishes Caregiver's Guide on Alzheimer's Disease - GuruFocus
IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease - Big News Network.com
Why IGC Pharma Inc. stock stays undervaluedMarket Volume Summary & Expert Curated Trade Setups - Newser
Will IGC Pharma Inc. (IGS1) stock beat growth indexesShare Buyback & Verified Trade Idea Suggestions - Newser
IGC Pharma (NYSE American: IGC) backs expert-led Alzheimer's caregiver guide - Stock Titan
How IGC Pharma Inc. stock reacts to weak economyWeekly Risk Summary & Reliable Volume Spike Trade Alerts - Newser
What drives IGC Pharma Inc stock pricePortfolio Allocation Tips & Buy Sell Signal Notifications - earlytimes.in
New Strong Buy Stocks for Oct. 24: IGC, ASM and More - MSN
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Fact - GuruFocus
IGC Pharma (IGC) Advances Alzheimer's Research with AI-Driven Ap - GuruFocus
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Tr - PharmiWeb.com
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Weatherford Democrat
IGC Pharma (NYSE: IGC) Uses MINT-AD AI to Map Socioeconomic Alzheimer’s Risks - Stock Titan
An analyst sees good growth prospects for IGC Pharma Inc (IGC) - Setenews
Will IGC Pharma Inc. stock benefit from AI adoption2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Is IGC Pharma Inc. (IGS1) stock considered safe havenEarnings Summary Report & AI Forecast Swing Trade Picks - newser.com
Is IGC Pharma Inc. (IGS1) stock undervalued after correction2025 Market Overview & Technical Pattern Based Signals - newser.com
Is IGC Pharma Inc. stock a contrarian opportunityWeekly Gains Report & Risk Controlled Swing Alerts - newser.com
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):